BC Advantage - 2022 Issue 4
Substance Use Disorder Treatment Incentive Program Receives Go Ahead from the OIG
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an Office of Inspector General advisory opinion involving a contingency management program for substance use disorder treatment. It explains the general compliance and fraud-and-abuse context, the advisory opinion’s limited scope, and why the ruling matters to organizations exploring incentive-based treatment models. The piece is aimed at readers who follow healthcare compliance, behavioral health programs, and federal oversight of treatment incentives.
Why This Topic Matters
It highlights how federal fraud-and-abuse review can affect incentive-based treatment programs for substance use disorder and why advisory opinions can be important for organizations evaluating program design and compliance risk.
What You Will Learn
- The federal compliance concerns that can arise with incentive-based substance use disorder treatment programs.
- The role of an OIG advisory opinion in evaluating a contingency management arrangement.
- The general limits and scope of an advisory opinion issued to a specific requestor.
- Why the opinion may be relevant to behavioral health and substance use disorder program administrators.
Who Should Read This
- Healthcare compliance professionals
- Behavioral health administrators
- Substance use disorder treatment program leaders
- Medical billing and coding professionals
- Healthcare attorneys and regulatory staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com